

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2019

---

**InfuSystem Holdings, Inc.**  
(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**001-35020**  
(Commission File Number)

**20-3341405**  
(I.R.S. Employer Identification No.)

**31700 Research Park Drive**  
**Madison Heights, Michigan 48071**  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (248) 291-1210

**Not Applicable**  
(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities Registered Pursuant to Section 12(b) of the Act:**

Title of Each Class	Trading Symbol(s)	Name of Each Exchange on which Registered
Common Stock, par value \$0.0001 per share	INFU	NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 2.02. Results of Operations and Financial Condition.**

On August 14, 2019, InfuSystem Holdings, Inc. (the “Company”) issued a press release reporting its financial results for the second quarter of 2019. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 of this Current Report on Form 8-K and the press release attached hereto as Exhibit 99.1 shall not be deemed “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of such section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits**

<b>Exhibit No.</b>	<b>Description</b>
99.1	<a href="#"><u>Press Release of InfuSystem Holdings, Inc., dated August 14, 2019</u></a>

---

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INFUSYSTEM HOLDINGS, INC.

By: /s/ Gregory W. Schulte

Gregory W. Schulte  
Chief Financial Officer

Dated: August 14, 2019



InfuSystem Holdings, Inc.  
31700 Research Park Drive  
Madison Heights, MI 48071  
248-291-1210

**CONTACT:** Joe Dorame, Joe Diaz & Robert Blum  
Lytham Partners, LLC  
602-889-9700

## INFUSYSTEM HOLDINGS, INC. REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS

*“Increase of 20.2% in Revenue vs. Same Prior Year Period as First Phase of Market Share Gains Significantly Impact Net Revenues.”*

MADISON HEIGHTS, MICHIGAN, August 14, 2019—InfuSystem Holdings, Inc. (NYSE American LLC: INFU) (“InfuSystem” or the “Company”), a leading national provider of infusion pumps and related services for the healthcare industry in the United States and Canada, today reported financial results for the second quarter ended June 30, 2019.

### Second Quarter Highlights:

- Net revenues for the three and six months ended June 30, 2019 were \$19.7 million and \$37.9 million, respectively, a \$3.3 million, or 20.2%, increase and \$5.0 million, or 15.3%, increase, respectively, from the same prior year periods.
- Net income for the quarter ended June 30, 2019 was \$0.4 million compared to a net loss of \$0.5 million for the same prior year period. Net loss year-to-date June 30, 2019 was \$0.6 million compared to a net loss of \$0.3 million year-to-date June 30, 2018.
- Adjusted earnings before income taxes, depreciation, and amortization (“Adjusted EBITDA”) for the three and six months ended June 30, 2019 was \$4.5 million and \$7.6 million, respectively, a \$1.4 million, or 42.6%, increase and \$0.9 million, or 13.4%, increase, respectively, from the same prior year periods.
- Cash flows provided by operating activities were \$4.3 million year-to-date, a decrease of \$0.5 million, or 10.9%, from the same prior year period, primarily due to a net increase in the change in accounts receivable of \$2.9 million related to our growth.

Commenting on the second quarter, Richard DiIorio, chief executive officer of InfuSystem, said, “We are operating according to plan, and as discussed in prior periods, we are starting to see the impact of the market share gains in our oncology business that began last year with elastomerics and is continuing this year with electronic pumps. We are also benefiting from growth in our pain management and infusion products markets. In addition to the market share gains, we are continuing to execute on a multiyear upgrade in revenue cycle management practices. Every additional dollar collected for services that have already been delivered is additive to revenue, earnings, EBITDA and cash flow.”

Mr. DiIorio continued, “I am, of course, pleased with our results in the first half of the year. The first phase involves primarily the market share gains made last year from elastomerics. In the second phase, we are completing the larger market share gains in electronic pumps resulting from our largest direct competitor changing its business model. The financial impact from the second phase market share gains will be seen in our financial results for the second half of 2019 and the first half of 2020.”

Mr. DiIorio concluded, “We continue to build the infrastructure to absorb this growth by adding strong talent to our already outstanding team, investing in our physical facilities and adding to and replenishing our already best-in-class fleet of electronic pumps. The benefits of these investments will not only enable our current growth, but we expect to contribute to long-term profitability and ongoing value creation for our shareholders.”

**Conference Call**

The Company will conduct a conference call for investors on Wednesday, August 14, 2019 at 9:00 a.m. Eastern Time to discuss second quarter 2019 results. The conference call may also include a discussion of Company developments, forward-looking statements and other material information about business and financial matters. To participate in this call, please dial (833) 366-1127 or (412) 902-6773, or listen via a live webcast, which is available in the investors section of the Company’s website at <https://ir.infusystem.com/>. A replay of the call will be available by visiting <https://ir.infusystem.com/> for the next 90 days or by calling (877) 344-7529 or (412) 317-0088, confirmation code 10134095, through August 21, 2019.

### **Condensed Consolidated Financial Statements**

Certain balances in the condensed consolidated financial statements for the quarter and year-to-date ended June 30, 2018 have been reclassified to be consistent with the quarter and year-to-date ended June 30, 2019 presentation in accordance with GAAP.

### **Non-GAAP Measures**

This press release contains information prepared in conformity with GAAP as well as non-GAAP financial information. The Company believes that the non-GAAP financial measures presented in this press release provide useful information to the Company's management, investors, and other interested parties about the Company's operating performance because they allow them to understand and compare the Company's operating results during the current periods to the prior year periods in a more consistent manner. This non-GAAP information should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP, and similarly titled non-GAAP measures may be calculated differently by other companies. The Company calculates those non-GAAP measures by adjusting for non-recurring items that are not part of the normal course of business and that the Company's management does not believe will have similar comparable year-over-year items or for non-operating items. A reconciliation of those measures to the most directly comparable GAAP measures is provided below.

### **About InfuSystem Holdings, Inc.**

InfuSystem Holdings, Inc. is a leading provider of infusion pumps and related services to hospitals, oncology practices and other alternate site healthcare providers. Headquartered in Madison Heights, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, Massachusetts and Ontario, Canada. The Company's stock is traded on the NYSE American LLC under the symbol INFU.

### **Forward-Looking Statements**

*The financial results in this press release reflect preliminary results, which are not final until the Company's Form 10-Q for the quarter ended June 30, 2019 is filed. In addition, certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements relating to future actions, business plans, objectives and prospects, future operating or financial performance. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," "strategy," "future," "likely," variations of such words, and other similar expressions, as they relate to the Company, are intended to identify forward-looking statements. Forward-looking statements are subject to factors, risks and uncertainties that could cause actual results to differ materially, including, but not limited to, our dependence on estimates of collectible revenue, potential litigation, changes in third-party reimbursement processes, changes in law and other risk factors disclosed in the Company's most recent annual report on Form 10-K and, to the extent applicable, quarterly reports on Form 10-Q. All forward-looking statements made in this press release speak only as of the date hereof. We do not undertake any obligation to update any forward-looking statements to reflect future events or circumstances, except as required by law.*

*Additional information about InfuSystem Holdings, Inc. is available at [www.infusystem.com](http://www.infusystem.com).*

FINANCIAL TABLES FOLLOW

**INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
**(UNAUDITED)**

	As of	
<i>(in thousands, except share data)</i>	June 30, 2019	December 31, 2018
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 1,702	\$ 4,318
Accounts receivable, net	11,218	9,593
Inventories	2,742	2,254
Other current assets	1,368	1,372
Total current assets	17,030	17,537
Medical equipment for sale or rental	1,927	1,601
Medical equipment in rental service, net of accumulated depreciation	28,873	23,488
Property & equipment, net of accumulated depreciation	1,539	1,445
Intangible assets, net	17,616	19,865
Operating lease right of use assets	5,182	-
Other assets	194	137
Total assets	\$ 72,361	\$ 64,073
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
Current liabilities:		
Accounts payable	\$ 10,206	\$ 7,091
Current portion of long-term debt	6,084	4,903
Other current liabilities	4,244	2,796
Total current liabilities	20,534	14,790
Long-term debt, net of current portion	27,478	28,842
Deferred income taxes	76	-
Operating lease liabilities, net of current portion	4,021	-
Total liabilities	52,109	43,632
Stockholders' equity:		
Preferred stock, \$.0001 par value: authorized 1,000,000 shares; none issued	-	-
Common stock, \$.0001 par value: authorized 200,000,000 shares; issued and outstanding 23,237,703 and 19,719,214, respectively, as of June 30, 2019 and 23,095,513 and 19,577,024, respectively, as of December 31, 2018	2	2
Additional paid-in capital	83,557	83,167
Retained deficit	(63,307)	(62,728)
Total stockholders' equity	20,252	20,441
Total liabilities and stockholders' equity	\$ 72,361	\$ 64,073

See accompanying notes to unaudited condensed consolidated financial statements.

**INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**  
**(UNAUDITED)**

<i>(in thousands, except share and per share data)</i>	Three Months Ended		Six Months Ended	
	June 30		June 30	
	2019	2018	2019	2018
Net revenues	\$ 19,723	\$ 16,415	\$ 37,916	\$ 32,898
Cost of revenues	8,367	6,729	16,219	12,975
Gross profit	11,356	9,686	21,697	19,923
Selling, general and administrative expenses:				
Amortization of intangibles	1,124	1,165	2,249	2,352
Selling and marketing	2,476	2,326	5,078	4,627
General and administrative	6,785	6,399	13,819	12,560
Total selling, general and administrative	10,385	9,890	21,146	19,539
Operating income (loss)	971	(204)	551	384
Other expense:				
Interest expense	(488)	(296)	(948)	(611)
Other (expense) income	(39)	1	(60)	(10)
Income (loss) before income taxes	444	(499)	(457)	(237)
Provision for income taxes	(63)	(6)	(122)	(64)
Net income (loss)	\$ 381	\$ (505)	\$ (579)	\$ (301)
Net income (loss) per share:				
Basic	\$ 0.02	\$ (0.02)	\$ (0.03)	\$ (0.02)
Diluted	0.02	(0.02)	(0.03)	(0.02)
Weighted average shares outstanding:				
Basic	19,708,422	22,703,415	19,644,590	22,751,318
Diluted	20,583,434	22,703,415	19,644,590	22,751,318

See accompanying notes to unaudited condensed consolidated financial statements.



**INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**(UNAUDITED)**

<i>(in thousands)</i>	<b>Six Months Ended</b>	
	<b>June 30</b>	
	<b>2019</b>	<b>2018</b>
<b>NET CASH PROVIDED BY OPERATING ACTIVITIES</b>	<b>\$ 4,319</b>	<b>\$ 4,846</b>
<b>INVESTING ACTIVITIES</b>		
Purchase of medical equipment, property and equipment	(7,893)	(2,743)
Proceeds from sale of medical equipment, property and equipment	1,333	1,720
<b>NET CASH USED IN INVESTING ACTIVITIES</b>	<b>(6,560)</b>	<b>(1,023)</b>
<b>FINANCING ACTIVITIES</b>		
Principal payments on term loans, capital lease obligations and other financing	(2,256)	(3,708)
Cash proceeds from other financing	2,024	-
Debt issuance costs	(3)	-
Common stock repurchased to satisfy statutory withholding on employee stock based compensation plans	(208)	(5)
Common stock repurchased as part of Repurchase Program	-	(1,264)
Cash proceeds from stock plans	68	46
<b>NET CASH USED IN FINANCING ACTIVITIES</b>	<b>(375)</b>	<b>(4,931)</b>
<b>Net change in cash and cash equivalents</b>	<b>(2,616)</b>	<b>(1,108)</b>
<b>Cash and cash equivalents, beginning of period</b>	<b>4,318</b>	<b>3,469</b>
<b>Cash and cash equivalents, end of period</b>	<b>\$ 1,702</b>	<b>\$ 2,361</b>

See accompanying notes to unaudited condensed consolidated financial statements.

**INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES**  
**GAAP TO NON-GAAP RECONCILIATION**  
**(UNAUDITED)**

**NET INCOME (LOSS) TO ADJUSTED EBITDA:**

<i>(in thousands)</i>	Three Months Ended June 30		Six Months Ended June 30	
	2019	2018	2019	2018
GAAP net income (loss)	\$ 381	\$ (505)	\$ (579)	\$ (301)
Adjustments:				
Interest expense	488	296	948	611
Income tax provision	63	6	122	64
Depreciation	1,896	1,625	3,676	3,253
Amortization	1,124	1,165	2,249	2,352
<b>Non-GAAP EBITDA</b>	<b>\$ 3,952</b>	<b>\$ 2,587</b>	<b>\$ 6,416</b>	<b>\$ 5,979</b>
Stock compensation costs	284	265	530	391
Early termination fees for capital leases	-	-	190	-
Shareholder costs	-	147	-	147
Exited facility costs	-	44	6	44
Management reorganization/transition costs	-	90	45	137
ASC 842 accounting principle change	108	-	108	-
Certain other non-recurring costs	179	40	347	40
<b>Non-GAAP Adjusted EBITDA</b>	<b>\$ 4,523</b>	<b>\$ 3,173</b>	<b>\$ 7,642</b>	<b>\$ 6,738</b>
GAAP Net Revenues	\$ 19,723	\$ 16,415	\$ 37,916	\$ 32,898
<b>Non-GAAP Adjusted EBITDA Margin</b>	<b>22.9%</b>	<b>19.3%</b>	<b>20.2%</b>	<b>20.5%</b>

Non-GAAP Adjusted EBITDA Margin is defined as Non-GAAP Adjusted EBITDA as a percentage of GAAP Net Revenues.